home / stock / knte / knte news

KNTE News and Press, Kinnate Biopharma Inc. From 02/14/23

Stock Information
Company Name: Kinnate Biopharma Inc.
Stock Symbol: KNTE
Market: NASDAQ
Website: kinnate.com
Menu
KNTE KNTE Quote KNTE Short KNTE News KNTE Articles KNTE Message Board
Get KNTE Alerts

News, Short Squeeze, Breakout and More Instantly...
KNTE - Kinnate Biopharma gets FDA fast track designation for its bile duct cancer treatment

Kinnate Biopharma ( NASDAQ: KNTE ) on Tuesday said the U.S. Food and Drug Administration (FDA) had granted a fast track designation to its inhibitor KIN-3248 for the treatment of bile duct cancer. The FDA granted the designation to KIN-3248 for the treatment of patients with unres...
KNTE - Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

SAN FRANCISCO and SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate’...

KNTE - Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference

SAN FRANCISCO and SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan , will participate in a fireside chat at the SVB Secu...

KNTE - Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director

SAN FRANCISCO and SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, Jill DeSimone, who will join effe...
KNTE - Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242...

KNTE - Kinnate Biopharma GAAP EPS of -$0.70 misses by $0.10

Kinnate Biopharma press release ( NASDAQ: KNTE ): Q3 GAAP EPS of -$0.70 misses by $0.10 . Cash and Cash Equivalents and Investments Position: As of September 30, 2022, the total of cash and cash equivalents and investments was $262.1 million, excluding cash from its&#x...

KNTE - Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates

Cash, cash equivalents and investments of $262.1 million as of September 30, 2022; cash runway expected to fund operations into mid-2024 SAN FRANCISCO and SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clini...
KNTE - Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

KIN-2787 cleared the predicted efficacious dose at 300 mg bid; dose escalation continues with maximum tolerated dose not yet determined KIN-2787 achieved meaningful exposures that were dose proportional and exceeded the predicted efficacious thresholds based on p...

KNTE - FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Clinical-stage oncology company Kinnate Biopharma ( NASDAQ: KNTE ) on Wednesday said it had got a fast track designation from the U.S. FDA for its inhibitor KIN-2787 for the treatment of patients with melanoma, the most serious type of skin cancer. The exact indication for...

KNTE - Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor

SAN FRANCISCO and SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate&...
Previous 10 Next 10